Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Uveitis Clear all
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery

NCT01384266
View directory record Official record
Conditions
Intraocular Inflammation
Interventions
Not listed
Lead sponsor
Associated Eye Care, Minnesota
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Edgewood, Kentucky • Stillwater, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 20, 2026, 11:12 PM EDT
Completed No phase listed Observational

Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases

NCT00357071
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 20, 2026, 11:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
View directory record Official record
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 20, 2026, 11:12 PM EDT
Not yet recruiting Phase 1 Interventional

A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis

NCT07427628
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
TRX103
Biological
Lead sponsor
Quan Dong Nguyen
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

NCT03828019
View directory record Official record
Conditions
Uveitis
Interventions
Adalimumab (ADA), Conventional immunosuppression (CON)
Biological · Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Early Phase 1 Interventional

A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome

NCT01693640
View directory record Official record
Conditions
Female Patients With Behcet's Syndrome
Interventions
Abatacept
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 20, 2026, 11:12 PM EDT
Completed No phase listed Observational

Journey of Patients With Vasculitis From First Symptom to Diagnosis

NCT03410290
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatous Vasculitis, Temporal Arteritis, Giant Cell Arteritis, Granulomatosis With Polyangiitis, Wegener Granulomatosis, Henoch Schonlein Purpura, IgA Vasculitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Urticarial Vasculitis
Interventions
Online Questionnaire
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

NCT02623426
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 20, 2026, 11:12 PM EDT
Completed No phase listed Observational

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

NCT00116090
View directory record Official record
Conditions
Uveitis, Cancer, Infection, Mortality, Immunosuppression
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
6,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Baltimore, Maryland • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

PEMF: an Adjunct Therapy for Anterior Uveitis

NCT01154010
View directory record Official record
Conditions
Anterior Uveitis, Iritis
Interventions
PEMF, PEMF Placebo
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 20, 2026, 11:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography

NCT01746537
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 20, 2026, 11:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

NCT03145025
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Retisert, Fluocinolone Acetonide Intravitreal Implant
Device · Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Results available

Efalizumab to Treat Uveitis

NCT00280826
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Efalizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 20, 2026, 11:12 PM EDT
Withdrawn No phase listed Observational

Microbiome as a ThErapeutic Response Biomarker

NCT04721743
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

Daclizumab and Sirolimus to Treat Uveitis

NCT00078689
View directory record Official record
Conditions
Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Not applicable Interventional

Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

NCT06585670
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
Calm Health - smartphone application
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 11:12 PM EDT
Completed No phase listed Observational

The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

NCT00331331
View directory record Official record
Conditions
Uveitis, Vasculitis, Ocular Inflammatory Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 20, 2026, 11:12 PM EDT
Completed No phase listed Observational

Differences in Genes and Proteins in Active and Controlled Uveitis

NCT00357266
View directory record Official record
Conditions
Ocular Inflammatory Disease, Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 2 Interventional

Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis

NCT00043667
View directory record Official record
Conditions
Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Methotrexate and Mycophenolate Mofetil for UVEITIS

NCT01829295
View directory record Official record
Conditions
Uveitis
Interventions
Mycophenolate mofetil, Methotrexate, Prednisone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 1 Interventional

Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis

NCT01781936
View directory record Official record
Conditions
Uveitis Affecting the Posterior Segment
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Glenn Jaffe
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 20, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study in Refractory Behcet's Disease

NCT00995709
View directory record Official record
Conditions
Behcet Disease
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Arlington, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 20, 2026, 11:12 PM EDT